Insider buying last 90 days
No open-market insider purchases were filed for GMAB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Genmab's week centers on petosemtamab, which combined with Merck's Keytruda cut death risk by 50% in first-line head and neck cancer patients in the Phase 3 LiGeR-HN1 trial, meeting both overall survival and objective response rate endpoints. Shares also rose 4% after partner Johnson & Johnson secured FDA approval for Rybrevant Fasbro in head and neck cancer, on which Genmab is set to receive royalties of 8% to 10% on net sales. Several directors and CEO Jan van de Winkel disclosed share sales during the period, alongside a capital increase tied to employee warrant exercises.
GMAB closed at $51.37, down 0.7%, with the stock trading well above both its 50-day average of $41.15 and 200-day average of $31.54, reflecting a sustained uptrend; the 1-month return stands at 35.8% and the 1-year return at 68.6%. The GekkoIndex reads 53.4, placing the stock in the Neutral zone. Price sits 9.5% above Gekko Fair Value of $46.91.
The next earnings date is 16 February 2027, 94 days out, beyond a typical 20-trading-day hold. Over the last 30 days, one unusual options signal was recorded, with call premium of $4.3 million against no put premium. Consensus among 9 analysts stands at 8 buy and 1 hold ratings, with a consensus target of $65.11. Seasonality over the next 20 trading days has averaged -2.2% across 5 years, rising in 2 of them.
Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.
Genmab scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $51.37 is above the 50-day ($41.15) and 200-day ($31.54) averages, and the 50-day is above the 200-day.
See the chart53.4, Neutral
Reading 53.4 is in the Neutral zone.
See the GekkoIndex9.0% above
Price is 9% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 93 days
Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.
See earnings−1.4% on average
From this point in the calendar, the next 20 trading days averaged −1.4% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Genmab closed at $51.37 on Nov 13, 2026, +68.6% over the past year, inside a 52-week range of $23.62 to $59.97.
Use the left and right arrow keys to read daily values.
Put GMAB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Genmab works in biopharmaceuticals, focusing on discovering and developing antibody-based treatments, mainly for cancer along with a handful of other serious conditions. It is known for its marketed antibody therapies, including a treatment for multiple myeloma and related blood cancers, one for thyroid eye disease, one used in chronic lymphocytic leukemia and multiple sclerosis, another for certain gastric, esophageal and lung cancers, and one aimed at cervical and ovarian cancers and other solid tumors.
Beyond its approved products, Genmab runs a wide pipeline of experimental antibodies at various clinical stages, targeting solid tumors and blood cancers, alongside roughly twenty early pre-clinical programs. Much of this work is carried out through partnerships rather than alone, with agreements covering commercialization and co-development, mRNA-based antibody research, and other joint development deals with several pharmaceutical and biotech partners.
Genmab was established in 1999 and is headquartered in Copenhagen, Denmark. Its shares trade under the ticker GMAB.
Genmab’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.4, in the Neutral zone, up 6.6 points over five sessions.
Up 6.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | −0.6% | +1.0% | ||
| Accumulation | 218 | +0.5% | +1.9% | ||
| Neutral (current zone) | 344 | +0.7% | +1.5% | ||
| Distribution | 43 | +2.4% | +6.7% | ||
| Selling | 3 | Too few readings yet | |||
Average GMAB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Genmab trades 9.0% above Gekko Fair Value of $47.13, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Genmab shares are worth, recalculated every trading day.
$47.13
Gekko Fair Value, Nov 14, 2026
9.0% Overvalued
At the end of Aug 2026 the price was 7.0% below the estimate.
No open-market insider purchases were filed for Genmab, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GMAB in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in GMAB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Genmab has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bearish flow on Oct 29, $4.29M in unusual premium.
0of the funds Gekko tracks hold GMAB.
Genmab reports on Feb 16, 2027 (93 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 16, 2027
93 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 5, 2026 | $0.56 est $0.36 | $1.19B est $1.20B | −2.7% |
| Aug 6, 2026 | $0.54 est $0.37 | $1.16B est $1.12B | +6.8% |
| May 7, 2026 | $0.13 est $0.19 | $896.0M est $905.8M | −5.2% |
| Feb 17, 2026 | $0.21 est $0.37 | $1.06B est $1.07B | −2.9% |
| Nov 6, 2025 | $0.65 est $0.45 | $1.02B est $1.01B | −1.8% |
| Aug 7, 2025 | $0.54 est $0.34 | $924.8M est $952.6M | −0.4% |
| May 8, 2025 | $0.31 est $0.23 | $726.0M est $755.5M | −6.0% |
| Feb 12, 2025 | $0.84 est $0.28 | $891.4M est $791.9M | +10.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Genmab is $65.10, +26.7% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $56 | +9.0% |
| Nov 6 | Truist Financial | $67 | +30.4% |
| Nov 6 | Morgan Stanley | $57 | +11.0% |
| Nov 6 | H.C. Wainwright | $70 | +36.3% |
| Nov 6 | Bank of America Securities | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Genmab averaged −1.4% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.6% | 2 of 5 |
| Next 10 trading days | −0.9% | 2 of 5 |
| Next 15 trading days | +1.3% | 3 of 5 |
| Next 20 trading days | −1.4% | 2 of 5 |
| Next 30 trading days | −1.0% | 1 of 5 |
For scale, GMAB’s typical 20-trading-day move in either direction is about 6.9%.
Genmab’s market cap is $31.67B, with a P/E ratio of 44.2 and revenue of $4.30B over the last twelve months.
Coverage of Genmab this week reads positive: 5 positive, 3 neutral and 2 negative headlines.
Genmab’s market cap is $31.67B at the Nov 13, 2026 close of $51.37, with 616.6M shares outstanding. The shares trade on a P/E ratio of 44.2.
The consensus analyst 12-month price target for Genmab is $65.10, +26.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Genmab is overvalued: the Nov 13, 2026 close of $51.37 is 9.0% above Gekko Fair Value of $47.13. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Genmab is expected to report on Feb 16, 2027 (93 days away). Analysts expect earnings of $0.23 per share on revenue of $1.25B. Genmab beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.
Genmab’s 52-week high is $59.97 and its 52-week low is $23.62; it closed at $51.37 on Nov 13, 2026, +68.6% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Genmab over the last 30 days, with $4.29M of flagged premium in calls and $0 in puts. The latest, bearish flow, was on Oct 29, 2026 with $4.29M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.